| Dr David P Hutz, MD | |
|
40 Dallas Shopping Ctr, Dallas, PA 18612-1231 | |
| (570) 675-2000 | |
| (570) 675-1806 |
| Full Name | Dr David P Hutz |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Location | 40 Dallas Shopping Ctr, Dallas, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205895083 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | MD422703 (Pennsylvania) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr David P Hutz, MD 100 N Academy Ave, Danville, PA 17822-3034 Ph: (570) 271-6144 | Dr David P Hutz, MD 40 Dallas Shopping Ctr, Dallas, PA 18612-1231 Ph: (570) 675-2000 |
News Archive
Cardiac catheterizations have been a groundbreaking tool in the field of cardiology. This procedure offers a minimally invasive means for obtaining important information about the heart and its blood vessels, while also providing a less invasive treatment for certain heart conditions.
Isis Pharmaceuticals, Inc. announced today it has earned a $5 million milestone payment from Biogen Idec associated with the validation of an undisclosed target to treat a neurological disorder under its broad strategic collaboration with Biogen Idec to develop drugs to treat patients with neurological disorders.
A drug that targets a specific type of lung cancer shows a dramatic response in more than half of the people who take it. The drug, called crizotinib, has been in clinical trials since 2006, and the results from the largest group of patients to take it within the first of these clinical trials are being presented at the annual meeting of the American Society of Clinical Oncology.
There are about 10 million cases of TB globally each year and 1 in 3 people are infected with the TB bacterium. BCG is the most widely used vaccine worldwide, but its mechanism of protection is poorly understood. It is thought to prevent progression of infection to active TB but whether it protects against the acquisition of infection itself has not been investigated in humans.
LUCA Biologics, a biotechnology company co-founded by Dr. Jacques Ravel, announced today it will develop live biotherapeutics for widespread, unmet medical needs in women's health. Ravel will serve as LUCA's Chief Scientist.
› Verified 5 days ago
Dr. David Hunkele Moore, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 289 Follies Rd, Dallas, PA 18612 Phone: 570-675-6436 |